NASDAQ:SLGL

Sol-Gel Technologies Stock Forecast, Price & News

$14.70
+1.30 (+9.70 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.41
Now: $14.70
$15.23
50-Day Range
$8.75
MA: $11.51
$15.49
52-Week Range
$7.00
Now: $14.70
$16.69
Volume140,059 shs
Average Volume53,413 shs
Market Capitalization$299.73 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Sol-Gel Technologies logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLGL
CUSIPN/A
Phone972-8931-3429
Employees65
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.90 million
Book Value$2.57 per share

Profitability

Net Income$-24,610,000.00
Net Margins-273.92%

Miscellaneous

Market Cap$299.73 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Recap: Sol-Gel Technologies Q3 Earnings
November 12, 2020 |  finance.yahoo.com
Sol-Gel Technologies EPS beats by $0.09, beats on revenue
November 12, 2020 |  seekingalpha.com
Sol-Gel Technologies Ltd. Ordinary Shares (SLGL)
November 5, 2020 |  nasdaq.com
FDA accepts Sol-Gel application for rosacea cream
September 10, 2020 |  seekingalpha.com
Sol-Gel jumps on FDA acceptance of Epsolay NDA
September 10, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.16 out of 5 stars

Medical Sector

949th out of 2,021 stocks

Pharmaceutical Preparations Industry

447th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$14.70
+1.30 (+9.70 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLGL News and Ratings via Email

Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sol-Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions

Is Sol-Gel Technologies a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sol-Gel Technologies stock.
View analyst ratings for Sol-Gel Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Sol-Gel Technologies?

Wall Street analysts have given Sol-Gel Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sol-Gel Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sol-Gel Technologies' next earnings date?

Sol-Gel Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Sol-Gel Technologies
.

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) issued its quarterly earnings data on Wednesday, March, 3rd. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.13. The company had revenue of ($10.11) million for the quarter, compared to analysts' expectations of $1.62 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 48.54% and a negative net margin of 273.92%.
View Sol-Gel Technologies' earnings history
.

How has Sol-Gel Technologies' stock price been impacted by COVID-19?

Sol-Gel Technologies' stock was trading at $8.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLGL stock has increased by 78.2% and is now trading at $14.70.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SLGL?

2 brokers have issued 12 month price targets for Sol-Gel Technologies' shares. Their forecasts range from $21.00 to $21.00. On average, they expect Sol-Gel Technologies' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price.
View analysts' price targets for Sol-Gel Technologies
or view top-rated stocks among Wall Street analysts.

Who are Sol-Gel Technologies' key executives?

Sol-Gel Technologies' management team includes the following people:
  • Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 60, Pay $397k)
  • Mr. Gilad Mamlok, Chief Financial Officer (Age 53, Pay $364k)
  • Mr. John M. Vieira, U.S. Head of Commercialization (Age 51, Pay $284k)
  • Prof. David Avnir, Co-Founder
  • Dr. Itzik Yosef, Chief Operating Officer (Age 45)
  • Dr. Karine Neimann, VP of Projects & Planning and Chief Chemist (Age 50)

Who are some of Sol-Gel Technologies' key competitors?

What other stocks do shareholders of Sol-Gel Technologies own?

When did Sol-Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ acted as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

What is Sol-Gel Technologies' stock symbol?

Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sol-Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $14.70.

How much money does Sol-Gel Technologies make?

Sol-Gel Technologies has a market capitalization of $299.73 million and generates $22.90 million in revenue each year. The company earns $-24,610,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does Sol-Gel Technologies have?

Sol-Gel Technologies employs 65 workers across the globe.

What is Sol-Gel Technologies' official website?

The official website for Sol-Gel Technologies is www.sol-gel.com.

Where are Sol-Gel Technologies' headquarters?

Sol-Gel Technologies is headquartered at 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648.

How can I contact Sol-Gel Technologies?

Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The company can be reached via phone at 972-8931-3429 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.